,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny,breast,4', 'breast', 'mbc', 'destiny-breast04']
#asco22 | tells us about the #standingovation for the amazing results of the destiny-breast04 trial: a statistically significant and clinically meaningful benefit in pfs and os compared to standard-of-care treatment in pts with her2-low #mbc. 
Latest research in oncology | Breaking news, insights, interviews, live tweeting and updates from major conferences | Published by @ilpensiero | @think2it